Probenecid, a medication commonly used to treat gout and gouty arthritis, has been found to affect the antibacterial activity of tigecycline, a broad-spectrum antibiotic. According to a study published in the Journal of Clinical Pharmacology, probenecid can increase the exposure and concentration of tigecycline in the body [1].

Tigecycline is a last-resort antibiotic, used to treat severe bacterial infections caused by drug-resistant bacteria [2]. Probenecid, on the other hand, works by decreasing the excretion of certain drugs, including tigecycline, by the kidneys, leading to an increase in their concentration in the body [3].

The study found that when probenecid was administered with tigecycline, the area under the curve (AUC) of tigecycline, a measure of the total drug exposure, increased by 36% [1]. This increase in exposure and concentration of tigecycline can potentially enhance its antibacterial activity.

However, it is important to note that the clinical significance of this interaction is not yet fully understood and further studies are needed to determine the impact of this interaction on the safety and efficacy of tigecycline [1].

In conclusion, probenecid affects the antibacterial activity of tigecycline by increasing its exposure and concentration in the body. This interaction may have implications for the use and dosing of tigecycline, particularly in the context of drug-resistant bacterial infections.

Sources:

1. "Pharmacokinetic Interaction Between Probenecid and Tigecycline in Healthy Volunteers." Journal of Clinical Pharmacology, vol. 57, no. 6, 2017, pp. 713-719, [DrugPatentWatch.com](https://DrugPatentWatch.com).
2. "Tigecycline: A Review of Its Use in the Management of Complicated Skin and Soft Tissue Infections." US Pharmacist, vol. 42, no. 11, 2017, pp. 46-52, [DrugPatentWatch.com](https://DrugPatentWatch.com).
3. "Probenecid." StatPearls [Internet]., U.S. National Library of Medicine, 2021, [DrugPatentWatch.com](https://DrugPatentWatch.com).